Glioblastoma multiforme (GBM) is the most common primary brain tumor and is a highly aggressive malignancy with a very poor prognosis.  Post-surgical therapy consisting of chemotherapy in combination with radiotherapy is currently the standard of care for glioma. Several chemotherapeutic agents including temozolomide are used to treat GBM. However, this treatment remains suboptimal with most patients dying within the first year of diagnosis despite aggressive therapy. This highlights the urgent need to develop new chemotherapeutic agents to treat GBM. We have identified SP-6-27  as a potent antiglioma agent.  The chromene SP-6-27  is active against four human glioma cell lines (T98, A172, LN18, and U87) and was particularly effective against A172 cell (IC50: 7.4 nM).   Overall anticancer activity was verified by one of the selected chromenes (SP-6-19 ) through the NCI 60 cell line screen.  Our data suggest that these novel chromenes should be further developed as potential therapeutic agents against GBM.

New substituted 4H-chromenes as antiglioma agents

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.